Posted by Michael Wonder on 09 Dec 2018
Transparency Commission publishes its opinion for Yescarta
7 December 2018 - Opinion published following an examination of written submissions on 5 December 2018.
The Commission considers that, in the current state of the data, YESCARTA provides a moderate improvement in actual benefit (ASMR III) in terms of effectiveness compared to the current management of patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma that is refractory or relapsed after at least two lines of systemic treatment.
